Neringa's Licence Portfolio
A novel platform for production of Viral-like Particles (VLPs) used as a single vaccine against a range of viruses, including HIV, HPV, or Ebola. The invention combines two technical innovations; core platform to generate non-infectious VLPs based on the modification of Mumps or Parainfluenza 5 viruses, and a ‘pseudotyping’ technology to incorporate viral glycoproteins of choice on the surface of VLPs. As a proof of concept, the platform was used in development of modified VLPs against HIV. When used as a vaccine, VLPs boosted the production of anti-HIV antibodies better than the native virus.
The present invention relates to a novel DNA delivery vector for targeted gene therapy, medical imaging and vaccination with increased efficacy over existing technologies. The platform comprises a phagemid hybrid with phage and recombinant adeno-associated virus (AAV) components.
A novel viral delivery vector with scope for more cost-effective commercial production over existing technologies. The platform comprises a phagemid hybrid with recombinant adeno-associated virus (AAV) components.
Researchers at Imperial College London have developed two novel modifications of bacteriophages to significantly improve their efficacy as vectors for targeted gene therapy, and exploit their advantages over eukaryotic viral vectors.
Suite of microRNAs for predicting cervical shortening and preterm birth that can be measured from blood samples taken in early pregnancy (from gestation week 12 onwards).
Novel truncated fragments of von Willebrand factor (VWF) engineered by a team at Imperial College London.